Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Filings indexed 559 across all filing types
Latest filing 2021-08-10 Earnings Release
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 10, 2021, reporting the issuance of a press release announcing financial results for the quarter ended June 30, 2021. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is not deemed "filed" for certain regulatory purposes. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of the earnings information. This matches the characteristics of an Earnings Release (ER) filing, which is the initial announcement of quarterly financial results with key highlights. The document length is 3633 characters, which is relatively short and consistent with an earnings release announcement rather than a full quarterly report or annual report. Therefore, the correct classification is Earnings Release (ER).
2021-08-10 English
FORM 4 SUBMISSION
Director's Dealing
2021-08-05 English
FORM 4 SUBMISSION
Director's Dealing
2021-07-16 English
FORM 4 SUBMISSION
Director's Dealing
2021-07-02 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-06-30 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-06-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.